biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon May 28, 2020 3:35pm

140 Views

Post# 31084274

RE:RE:RE:RE:Denali Therapeutics unveils BBB delivery system

JD,

When I saw this tweet from Stat News reporter Meghana Keshavan , I immediately thought of you.

"Hi! Does anyone want to talk to me about getting drugs past the blood-brain barrier? Lemme know -- I've got a deadline coming up fast."

https://twitter.com/megkesh/status/1265667435014713344?s=20

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale